Skip to main content

Table 2 The RPPA markers that showed significant modulations after 3 days of the RO4987655 treatment

From: Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Analyte Pvalue Pathway
ERK1/2-P-Thr202/Tyr204-rbm 0.00001 MAPK
EGFR-P-Tyr1068 0.0058 RTK
MKK4-P-Ser257/Thr261 0.0483 MAPK
MEK1/2-P-Ser217/221 0.00098 MAPK
Akt-P-Ser473 0.0034 Akt/metabolism
c-Met 0.0242 RTK
P53-P-Ser392 0.025 Cell cycle control
Cyclin D1 0.0302 Cell cycle control
C-Raf-P-Ser338 0.0371 MAPK
MEK2 0.0433 MAPK